Cell cycle regulation is orchestrated by a complex network of interactions between proteins,
enzymes, cytokines, and cell cycle signaling pathways, and is vital for cell proliferation …

Assessment of minimal residual disease (MRD) is becoming standard diagnostic care for
potentially curable neoplasms such as acute lymphoblastic leukemia. In multiple myeloma …

Therapies with novel mechanisms of action are needed for multiple myeloma (MM). B-cell
maturation antigen (BCMA) is expressed in most cases of MM. We conducted the first-in …

Flow cytometry has become a highly valuable method to monitor minimal residual disease
(MRD) and evaluate the depth of complete response (CR) in bone marrow (BM) of multiple …

Daratumumab (DARA) is a human CD38-specific IgG1 antibody that is in clinical
development for the treatment of multiple myeloma (MM). The potential for IgG1 antibodies …

The prognosis for patients multiple myeloma (MM) has improved substantially over the past
decade with the development of new, more effective chemotherapeutic agents and regimens …

Detecting persistent minimal residual disease (MRD) allows the identification of patients with
an increased risk of relapse and death. In this study, we have evaluated MRD 3 months after …

In recent years, several studies on large series of multiple myeloma (MM) patients have
demonstrated the clinical utility of flow cytometry monitoring of minimal residual disease …

The detection of minimal residual disease (MRD) in myeloma using a 0.01% threshold (10−
4) after treatment is an independent predictor of progression-free survival (PFS), but not …

The approach to the patient with relapsed or relapsed/refractory multiple myeloma (RRMM)
requires a careful evaluation of the results of previous treatments, the toxicities associated …